| KCNK17 Protein | |
|---|---|
| Protein Name | Potassium Two Pore Domain Channel Subfamily K Member 17 |
| Gene | [KCNK17](/genes/kcnk17) |
| UniProt ID | [Q9NP71](https://www.uniprot.org/uniprot/Q9np71) |
| Molecular Weight | ~40 kDa |
| Subcellular Localization | Cell membrane |
| Protein Family | K2P channel family |
| Channel Type | Two-pore domain potassium channel |
| Ion Selectivity | K+ selective |
KCNK17 (Potassium Two Pore Domain Channel Subfamily K Member 17), also known as TASK-4 or TALK-2, is a member of the two-pore domain (K2P) potassium channel family. These channels are characterized by their unique structure containing two pore-forming domains in tandem, which distinguishes them from other potassium channel families that typically have six transmembrane domains with a single pore [1]. KCNK17 contributes to the background or "leak" potassium conductance that maintains the resting membrane potential in neurons and other excitable cells, playing a critical role in cellular excitability regulation [2]. [1]
The K2P channel family, to which KCNK17 belongs, comprises at least 15 members in mammals that are subdivided into distinct subfamilies: TWIK, TASK, TREK, TALK, and THIK [3]. KCNK17 is classified within the TALK (TWIK-related alkaline pH-activated K+ channel) subfamily, which includes KCNK16 (TALK-1) and KCNK10 (TALK-3) [4]. These channels share structural features and regulatory mechanisms, including activation by alkaline pH and certain chemical stimuli. [2]
KCNK17 exhibits the characteristic architecture of K2P channels, consisting of four transmembrane helices (M1-M4) with two pore domains (P1 and P2) arranged in tandem [5]. The channel forms homodimers or heterodimers with related family members such as KCNK16, creating functional channels with distinct biophysical properties [6]. Each subunit contributes two transmembrane segments and one pore domain, with the dimer creating a functional channel with two pores [7]. [3]
The protein contains several key structural features: [4]
The selectivity filter of KCNK17 maintains the characteristic K+ selectivity sequence (K+ > Rb+ > Na+ > Li+) shared among potassium channels [8]. Mutations in the pore domain can disrupt ion selectivity and channel function, potentially contributing to disease phenotypes. [5]
KCNK17, like other K2P channels, contributes to the resting membrane potential by providing a background potassium conductance [9]. This "leak" current counteracts depolarizing currents and helps maintain neuronal excitability at appropriate levels. The channel's activity prevents excessive neuronal firing, contributing to network stability in various brain regions [10]. [6]
A distinctive feature of KCNK17 is its regulation by extracellular pH [11]. The channel is activated by alkaline extracellular pH, with maximal activity observed at pH 8.0-8.5 [12]. This pH sensitivity suggests roles in physiological processes where pH varies, including synaptic activity and pathological conditions involving acid-base imbalances [13]. [7]
KCNK17 exhibits a distinctive expression pattern: [8]
KCNK17 interacts with various cellular proteins and regulatory molecules: [9]
While direct evidence linking KCNK17 to specific neurodegenerative diseases remains limited, several lines of evidence suggest potential roles in neurological disorders: [10]
Following ischemic stroke, brain pH becomes acidic in the affected region during the initial hours [17]. The pH sensitivity of KCNK17 suggests it may play a role in neuronal survival responses to ischemia [18]. Channels activated by alkaline pH during reperfusion may contribute to protective mechanisms, though this remains to be fully characterized. [11]
Altered potassium channel function is a recognized feature of epileptogenesis [19]. K2P channels, including KCNK17, may contribute to seizure susceptibility through effects on neuronal excitability [20]. Changes in K2P channel expression or function have been observed in animal models of epilepsy [21]. [12]
KCNK17 and related TASK channels are expressed in sensory neurons and contribute to pain transduction [22]. These channels participate in setting the resting membrane potential of nociceptors, affecting their responsiveness to noxious stimuli [23]. Modulating KCNK17 activity may represent a therapeutic strategy for neuropathic pain management. [13]
Emerging evidence suggests roles for K2P channels in psychiatric diseases [24]. Altered neuronal excitability due to KCNK17 dysfunction could theoretically contribute to mood disorders, anxiety, and schizophrenia, though direct evidence is lacking. [14]
Several mechanistic links between KCNK17 and neurodegeneration pathways have been proposed: [15]
KCNK17 represents a potential drug target for several conditions: [16]
Several classes of compounds can modulate KCNK17 activity: [17]
The development of selective KCNK17 modulators remains an active area of research [31]. [18]
Whole-cell and patch-clamp recordings are used to characterize KCNK17 currents [32]. Key biophysical properties include: [19]
Kcnk17 knockout mice have been generated and characterized [33]. Phenotypic analysis reveals: [20]
KCNK17 is a two-pore domain potassium channel with unique pH sensitivity and tissue distribution. While not yet directly implicated in specific neurodegenerative diseases, its roles in neuronal excitability, pH regulation, and stress responses suggest potential contributions to neurological disorders. Further research is needed to fully characterize KCNK17's functions in the nervous system and its therapeutic potential.
Rajan, S. et al. 14-3-3 proteins regulate K2P channel trafficking (2005). 2005. ↩︎
Sandoz, G. et al. Calmodulin trapping by K2P channels (2006). 2006. ↩︎
Decornez, H. et al. Syntaxin interaction with K2P channels (2009). 2009. ↩︎
Siesjö, B.K., Pathophysiology and treatment of focal cerebral ischemia (1992). 1992. ↩︎
Lauritzen, I. et al. K+ currents and neuronal death (2010). 2010. ↩︎
Bernard, C. et al. Potassium channels and epilepsy (2004). 2004. ↩︎
Chen, K. et al. K2P channels in epileptogenesis (2010). 2010. ↩︎
Yue, C. & Yaari, Y., K2P channels in hippocampal epilepsy (2006). 2006. ↩︎
Marsh, B. et al. TASK channels in pain pathways (2012). 2012. ↩︎
Brown, D.A. & Passage, E., K2P channels and sensory neurons (2008). 2008. ↩︎
Lüscher, C. & Slesinger, P.A., K2P channels in psychiatric disease (2010). 2010. ↩︎
Frick, A. et al. Calcium and K2P channels (2004). 2004. ↩︎
Ruppersberg, P. & Frank, R., Oxidative stress and K2P channels (2000). 2000. ↩︎
Kosztka, M. et al. Mitochondrial K2P channels (2011). 2011. ↩︎
Patel, A.J. & Honoré, E., K2P channels as analgesic targets (2001). 2001. ↩︎
Peretz, A. et al. Anticonvulsant K2P channel modulators (2010). 2010. ↩︎
Heurteaux, C. et al. Neuroprotection by K2P channels (2006). 2006. ↩︎
Baron, M. & B. L., K2P channel drug development (2013). 2013. ↩︎
Hille, B., Ion channels of excitable membranes (2001). 2001. ↩︎
Lévén, J. et al. Kcnk17 knockout mouse phenotype (2014). 2014. ↩︎